Adaptive Biotechnologies (ADPT) Q2 2024 earnings summary

Executive summary

• Achieved 36% year-over-year MRD revenue growth, with MRD now comprising 82% of total revenue and clonoSEQ test volume up 36% to 18,520 tests.

• Operating expenses (excluding one-time items) decreased 15% year-over-year and 8% sequentially, with significant reductions across all segments.

• Net loss narrowed to $46.2 million from $47.8 million year-over-year.

• Cash, cash equivalents, and marketable securities totaled $291.9 million as of June 30, 2024, with first-half cash burn of ~$55 million, down from $81 million in the first half of 2023.

• Restructuring activities in 2024 led to $8.9 million in costs, including $7.2 million in impairment charges.

Financial highlights

• Q2 2024 total revenue was $43.2 million, down 12% year-over-year; MRD revenue rose 36% to $35.3 million, while Immune Medicine revenue fell 66% to $7.9 million.

• Adjusted EBITDA loss improved to $21.4 million from $24.8 million year-over-year.

• Operating expenses were $90.5 million, down 6% year-over-year; excluding $7.2 million impairment, down 14%.

• Cost of revenue increased to $19.3 million (45% of revenue) from $17.9 million (37%) year-over-year.

• Research and development expenses fell to $25.4 million from $32.2 million.

Outlook and guidance

• Raised full-year MRD revenue guidance to $140–$145 million from $135–$140 million.

• Lowered full-year operating expense guidance to $340–$350 million from $350–$360 million, excluding one-time costs.

• Full-year 2024 cash burn now projected at ~$115 million, improved from previous estimate of $130 million.

• EBITDA breakeven still targeted for the second half of 2025.

• Existing cash and marketable securities expected to fund operations for at least the next 12 months.